SEC Comment Letter for Axovant Gene Therapies Ltd. (CIK 0001636050) — Jan 16, 2020
Axovant Gene Therapies Ltd. (CIK 0001636050)
Date: Jan. 16, 2020 · CIK: 0001636050 · Accession: 0000000000-20-000411
AI Filing Summary & Sentiment
File numbers found in text: 333-235889
Letter
January 16, 2020 David Nassif Chief Financial Officer Axovant Gene Therapies Ltd. Suite 1, 3rd Floor 11-12 St. James' Square London SW1Y 4LB, United Kingdom Re:Axovant Gene Therapies Ltd. Registration Statement on Form S-3 Filed January 10, 2020 File No. 333-235889 Dear Mr. Nassif: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John McKenna, Esq.
Show Raw Text
January 16, 2020
David Nassif
Chief Financial Officer
Axovant Gene Therapies Ltd.
Suite 1, 3rd Floor
11-12 St. James' Square
London SW1Y 4LB, United Kingdom
Re:Axovant Gene Therapies Ltd.
Registration Statement on Form S-3
Filed January 10, 2020
File No. 333-235889
Dear Mr. Nassif:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Paul Fischer at 202-551-3415 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: John McKenna, Esq.